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mortality diff erence in ESRD. Detailed 
patient characteristics were not available 
in the study by van Dijk et al.;4 hence it 
is unclear what caused the remaining 
diff erence. Th e idea of using contrasting 
general population mortality rates as a 
backdrop when comparing ESRD mor-
tality in diff erent countries was briefl y 
explored in the original study by Held 
et al.;1 in an addendum to their article, 
the authors compared the differences 
in general population mortality with 
those recorded in the ESRD population 
in Japan, Europe, and the United States. 
General population mortality was lower 
in Japan than in the United States, but the 
diff erence was smaller than that recorded 
between the ESRD populations in the 
two countries, suggesting that some, 
but not all, of the diff erence in the ESRD 
population mortality might be attribut-
able to factors specifi c to the studied geo-
graphic locations. Interestingly, though, 
the general population mortality in the 
United States was found to be lower 
than that in Europe, thus magnifying 
rather than alleviating the diff erences 
noted between ESRD mortality rates 
in these two regions.1 A more detailed 
analysis of this kind was used by Wong 
et al.,5 who compared ESRD mortality 
in Asian Americans versus other races 
in the United States and showed that 
race-specifi c general population death 
rates explained more than half of the 
variation in mortality imparted by race. 
In this latter study, patients of diff erent 
races were not segregated in diff erent 
geographic locations (as in studies com-
paring patients from diff erent countries); 
hence the range of factors for which gen-
eral population mortality might account 
was narrowed down to race-specific 
genetic, cultural, and/or socioeconomic 
diversity. Th is study also suggested that 
the diff erences in ESRD mortality rate 
between Japan and the United States may 
not be due to practice-related factors, as 
Asian-American patients with ESRD had 
a mortality rate similar to that of their 
counterparts in Japan.
These studies suggest that general 
population mortality rate could be used 
in future studies examining outcome 
discrepancies in diff erent ESRD popula-
tions, along with detailed adjustments for 
individual patient characteristics. Some 
questions remain, though. It is unclear 
how valid such an approach would be in 
comparing large entities (such as mor-
tality in Europe versus Japan versus the 
United States), given the clearly signifi -
cant regional variations in both ESRD and 
general population mortality rates within 
these entities.3–5 It is also unclear how the 
logic of using general population mortal-
ity to alleviate the diff erences in ESRD 
mortality across continents would apply 
in the case of the United States, where 
ESRD mortality is highest (when com-
pared with those of Japan and Europe) 
and yet general population mortality is 
lower than that reported in Europe.1
At the end of the day we are still left  
with the question: what is the benefi t of 
comparing ESRD populations from dif-
ferent regions? Practice patterns are being 
monitored in the DOPPS in order to iden-
tify factors associated with survival and 
other outcomes. Th e study by van Dijk 
et al.4 has brought renewed attention to 
a tool that could enhance similar studies. 
But we must not forget that no matter how 
sophisticated our statistical methods are, 
the results of observational studies are 
mostly hypothesis-generating and can-
not serve as ultimate proof of causality. 
Th ey are at the same time indispensable 
to provide ideas that are worth exploring 
in randomized controlled trials.
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Weighing in on fistula failure
BS Dixon1
Obesity, though not commonly reported as a cause of fistula failure, may influence 
fistula survival by making it difficult to cannulate the vein and possibly by releasing 
adipokines, such as interleukin-6, tumor necrosis factor-α, plasminogen activator 
inhibitor-1, or adiponectin, that modulate the development of neointimal hyperpla-
sia and thrombosis leading to fistula failure.
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Once established, an autogenous arterio-
venous fi stula has the lowest failure rate 
and fewest complications of any vascu-
lar access used for hemodialysis. The 
mortality rate and annual cost are also 
lower for patients with an arteriovenous 
fi stula compared with patients undergo-
ing hemodialysis using an arteriovenous 
graft  or central venous catheter. No rand-
omized trial comparing diff erent modes of 
vascular access has been done to exclude 
the possible confounding eff ect of selec-
tion bias. Nonetheless, it is likely that the 
chronic infl ammatory eff ects and infec-
tion risk of graft s and catheters account 
for much of the diff erence in complica-
tions, costs, and survival. Encouragingly, 
through the efforts of the Fistula First 
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initiative, National Kidney Foundation–
Kidney Disease Outcomes Quality Initia-
tive (KDOQI) guidelines, and many local 
and regional initiatives, the rate of autoge-
nous fi stula placement in the United States 
has increased in recent years. However, so 
too has the prevalence of central venous 
catheters. Continued success at expanding 
the prevalence of autogenous fi stulae to 
include most people on hemodialysis will 
require ongoing attention to understand 
and treat the etiologies of fi stula failure.
Observational epidemiologic studies 
such as that reported by Kats et al.1 (this 
issue) are important for understanding 
possible risk factors for fi stula failure and 
focus future eff orts at improving outcomes. 
Th is report is one of a series of studies from 
this group using a prospective hemodialy-
sis access database to identify risk factors 
for access failure. Th e present study is the 
fi rst to identify obesity (body mass index 
≥ 30 kg/m2) as a risk factor for secondary 
fi stula failure (that is, access failure that 
occurs aft er the fi stula has matured into an 
access usable for hemodialysis; Figure 1). 
What is remarkable is the timing of the fi s-
tula failure. As Kats et al.1 note, early failure 
might be expected in an obese individual 
because of problems in cannulating deep 
vessels. Th is could lead to traumatic needle 
sticks or the need for additional procedures 
to elevate the vein. Indeed this group had 
previously reported a trend toward higher 
primary fi stula failure in people with obes-
ity. However, this trend toward primary fi s-
tula failure was not observed in the present 
study;1 the authors suggest that this might 
be due to the initiation of routine preop-
erative vascular mapping. Instead, in the 
present study, they observed a signifi cant 
increase in secondary fi stula failure starting 
shortly aft er the fi stula begins to be used 
for hemodialysis. How might obesity cause 
secondary fi stula failure?
Fistula failure is generally conceived 
of as bimodal, involving either primary 
failure of the access to mature into a fi s-
tula usable for hemodialysis or secondary 
failure occurring in a previously usable 
fi stula (Figure 1). Biologically this division 
makes sense. Th e early processes required 
for postsurgical healing as well as arterial 
and venous dilation are presumably dif-
ferent from the late biological processes 
maintaining a functional fi stula. Th ere are 
as yet no validated biological markers that 
distinguish these phases — maturation and 
maintenance. However, changes in vessel 
size and fi stula fl ow rate by duplex ultra-
sound can be used as a functional marker 
of fi stula maturation. Time-course studies 
using duplex ultrasound have suggested 
that many fistulae attain near-maximal 
fl ow rates and vein size within 4–8 weeks 
aft er creation.2 However, there is interpa-
tient variability, and some patients show 
substantial increases in fl ow rate beyond 
this time, suggesting that the biological 
maturation process in those patients is 
more prolonged.
Venous stenosis due to neointimal 
hyperplasia is the most commonly identi-
fi ed anatomic etiology of both primary and 
secondary fi stula failure.2 In primary fi stula 
failure, the stenosis typically occurs in the 
downstream vein within a few centimeters 
of the anastomosis, whereas stenoses in sec-
ondary fi stula failure can be more dispersed 
in the arteriovenous circuit. Other causes of 
primary failure include impaired arterial or 
venous dilation, thrombosis, the presence 
of accessory veins, or veins that are too deep 
to cannulate. Th ese entities may in some 
cases be treatable and the fi stula salvaged 
to be ultimately usable for hemodialysis. 
Th e pathogenesis of the venous neointimal 
hyperplasia that accounts for most fi stula 
failure has not been fully explored. Patho-
logically, the venous neointimal hyperplasia 
is a dense lesion composed predominantly 
of smooth muscle cells and extracellular 
matrix.3 Infi ltration by infl ammatory cells 
including macrophages and lymphocytes 
is also seen.3 Th ese venous stenoses lack 
the well-developed lipid core characteris-
tic of typical atherosclerotic lesions. It is 
likely that the early juxta-anastomotic and 
perianastomotic lesions are initiated by a 
combination of the surgical trauma and 
the hemodynamic stresses placed on the 
newly arterialized vein. Factors that initi-
ate late stenoses, particularly at sites outside 
of the juxta-anastomotic region, are uncer-
tain but probably include trauma from 
needle sticks or perivascular infi ltration. 
Once initiated, progression of neointimal 
hyperplasia is probably nurtured by the 
uremic environment of chronic kidney 
disease. Endothelial dysfunction, oxidative 
stress, and infl ammation, present in many 
patients with chronic kidney disease, are 
known to play a role in the progression of 
atherosclerosis.4 It is likely that these fac-
tors also promote and accelerate the pro-
gression of neointimal hyperplasia leading 
to fi stula failure.
Obesity is a known risk factor for athero-
sclerosis and thrombosis and could thereby 
increase the risk of fi stula failure. As part 
of the metabolic syndrome, patients 
with visceral obesity frequently have 
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Figure 1 | Hazards of obesity for fistula failure. IL-6, interleukin-6; TNF-α, tumor necrosis factor-
α; PAI-1, plasminogen activator inhibitor-1.
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associated insulin resistance, dyslipidemia, 
and hypertension that collectively are 
associated with increased cardiovascular 
risk.5 A chronic low-grade infl ammatory 
state may be the link between obesity and 
these other systemic metabolic factors 
leading to increased cardiovascular risk.6 
Increased visceral adipose tissue may incite 
an infl ammatory response with infl ux of 
macrophages and formation of giant cells. 
Moreover, it is now known that adipocytes 
and the associated vascular and immune 
cells within adipose tissue secrete a large 
number of proteins (adipokines) that can 
aff ect systemic infl ammation and the car-
diovascular system.6 Several well-described 
factors relevant to cardiovascular disease 
include interleukin-6, tumor necrosis fac-
tor-α, and plasminogen activator inhibi-
tor-1 (Figure 1). Interleukin-6 is secreted 
from adipocytes and other cells within adi-
pose tissue and acts on the liver to stimu-
late the production of a large number of 
acute-phase reactants, including C-reactive 
protein. Both interleukin-6 and C-reactive 
protein are markers of the systemic infl am-
matory response and strong independent 
markers of cardiovascular risk.7 C-reactive 
protein participates in the complement-
mediated removal of damaged vascular 
cells and may directly be involved in the 
pathogenesis of neointimal hyperplasia.8 
Tumor necrosis factor-α is produced by 
macrophages, and circulating levels are 
increased in obesity. Tumor necrosis fac-
tor-α produces endothelial dysfunction, 
vasoconstriction, and upregulation of 
endothelial expression of proinfl amma-
tory adhesion molecules such as vascular 
cell-adhesion molecule-1 and intercellular 
adhesion molecule-1, leading to increased 
infl ux of macrophages. Circulating levels 
of plasminogen activator inhibitor-1 are 
increased in obesity and, by decreasing 
fi brinolysis, may contribute to the increased 
risk of arterial and venous thrombosis.9
Not all adipokines promote inflam-
mation, endothelial dysfunction, or 
thrombosis, however. For instance, adi-
ponectin produced by adipocytes can act 
on endothelial cells to inhibit the eff ect of 
tumor necrosis factor-α to increase proin-
fl ammatory adhesion molecules and can 
increase the release of nitric oxide that 
may decrease the risk of thrombosis.10 Adi-
ponectin has also been reported to inhibit 
growth factor-mediated proliferation of 
vascular smooth muscle cells and thereby 
might inhibit progression of neointimal 
hyperplasia. Many of the adipokines, 
including adiponectin, are metabolized by 
the kidney and increased in chronic kidney 
disease. Whether increased levels of some 
of these benefi cial adipokines could con-
tribute to the so-called ‘reverse epidemiol-
ogy’ of obesity in end-stage renal disease 
is not known.
How might these various factors in 
obesity contribute to the increased fi stula 
failure observed by Kats et al.?1 Inspection 
of survival curves can give a sense of the 
timing of biological processes contribut-
ing to failure. Th e instantaneous rate of 
change in survival at any given time is 
known as the hazard or conditional fail-
ure rate. A constant hazard yields a sur-
vival curve with a simple exponential rate 
of decline (Figure 1, lower right graphs). 
A survival curve that varies signifi cantly 
from a simple exponential curve implies 
a time-dependant hazard or competing 
hazards (for example, a declining risk of 
thrombosis aft er surgery; Figure 1, upper 
right graphs). Although rarely reported in 
the medical literature, plotting of the haz-
ard as a function of time can help to detect 
whether the hazard is constant or variable 
and may give a better sense of the cause(s) 
of failure. In the study by Kats et al.,1 the 
hazard for obese patients compared with 
normal and overweight patients appears 
to be time dependent, occurring prima-
rily between 100 and 200 days aft er fi stula 
placement. Beyond that time, the hazard 
appears similar between the groups. (Th e 
apparent lack of fi stula failure before about 
100 days is an artifact due to elimination 
of patients who had primary fi stula fail-
ure from this analysis of secondary fi s-
tula failure.) Although the authors do not 
show a hazard plot, they do report that the 
interaction between time and obesity on 
secondary fi stula failure reached border-
line signifi cance (P = 0.065), suggesting 
that the possibility of a time-dependent 
interaction between obesity and the early 
initiation of hemodialysis cannot be com-
pletely ignored. One early hazard in obes-
ity might be problems with perivascular 
infi ltration during early cannulation that 
leads to infl ammation and thrombosis. 
However, an earlier study by this group 
did not fi nd this to be a problem. Alterna-
tively, the balance of circulating factors in 
obesity that promotes thrombosis or fi s-
tula failure might be slowly reversed with 
progressive hemodialysis, thus decreas-
ing the subsequent hazard. Finally, as the 
authors suggest, obesity may promote 
a constant hazard for secondary fi stula 
failure through its effects on systemic 
infl ammation, as discussed above, to pro-
mote myointimal hyperplasia and fi stula 
thrombosis. Th is would be a comforting 
relief from the complex paradox of ‘reverse 
epidemiology’ in end-stage renal disease.
As Kats et al.1 note, the eff ect of obes-
ity on fi stula failure has not been seen in 
other studies. Th is suggests that there are 
unique characteristics of this population 
or environment that contribute to the risk. 
Th is report is the fi rst but is unlikely to be 
the only one to show a risk of fi stula failure 
with obesity. Promoting the increased use 
of fi stulae requires tackling the problems 
that limit its use. It is important to continue 
to explore and understand the causes of 
fi stula failure so that the prevalence and 
survival of fi stulae can be improved for all 
patients on hemodialysis.
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